CLEARWATER, Fla.--(BUSINESS WIRE)--Bovie Medical Corporation (NYSE:BVX), a maker of medical devices and supplies, and the developer of J-Plasma®, a patented new surgical product, today announced that it has appointed Shawn D. Roman as Director of Research & Development, effective October 27. In this newly-created position, Mr. Roman will be responsible for the further development and execution of the Company’s product portfolio from research through product launch.
Prior to joining Bovie, Mr. Roman worked as General Manager, Co-Innovation and, earlier, as Engineering Manager at Coorstek Medical (formerly Innovative Medical Device Solutions). Before that, he spent 14 years with Biomet Microfixation, Inc., a business division of Biomet, Inc., in several roles, including Vice President of Research & Development, Director of Development Engineering and Senior Development Engineer.
“This appointment represents an important step in our strategy to take advantage of Bovie’s existing R&D pipeline and leverage the capabilities of our in-house design team and our state-of-the-art manufacturing facilities,” said Robert L. Gershon, Chief Executive Officer. “In the second quarter of this year, we announced our first new major core product launch, and we are working on several initiatives to expand our product portfolio to drive future business growth.
“Shawn has extensive experience in developing products, leading research teams, and managing research collaborations. His skills represent an important asset for the Company, and we look forward to accelerating the pace of our product development, while maintaining Bovie’s reputation for quality and efficiency,” Mr.Gershon noted.
Mr. Roman holds a Bachelor of Science in Mechanical Engineering from the University of Florida and a Bachelor of Science in Physics from Jacksonville University. During his career, he has participated in several professional training programs on project management, leadership, and product development. Mr. Roman has been awarded non-qualified stock options to purchase 30,000 shares of Bovie common stock, exercisable at the closing price as of November 3, 2014. The options shall vest and be exercisable in four equal annual installments beginning on the first anniversary of the effective date.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices and supplies, as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal thermal spread and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.
Cautionary Statement on Forward-Looking Statements
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Reports on Forms 10-K/A and 10-Qs for the year ended December 31, 2013 and the quarters ended March 31, 2014, and June 30, 2014. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.